# US 2017/0362311 A1 · Methods and compositions for regulating iron homeostasis by modulation of bmp-6

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0362311 A1
- Document ID: US20170362311A1
- Status: Published application
- Kind: A1
- Application number: 15/599,420
- Filed: 2017-05-18
- Published: 2017-12-21
- Earliest claimed: 2008-11-13
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Herbert Y. Lin; Jodie Babitt
- Web page: https://patentgrep.com/patent/US20170362311A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/06: Antianaemics
- C07K 16/22: against growth factors {; against growth regulators}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.

## Claims

### Claim 1

A method of increasing serum transferrin saturation in a subject, the method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds mature bone morphogenetic protein-6 (BMP-6) or fragments thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein administration of said composition inhibits liver hepcidin mRNA production.

### Claim 3 (depends on 1)

The method of claim 1, wherein administration of said composition inhibits hepatic hepcidin expression.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a human and administration of said composition inhibits hepcidin expression in human hepatic cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody binds BMP-7.

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody specifically binds BMP-6 with higher affinity than BMP-7.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody binds BMP-6 with at least 5-fold greater affinity than BMP-7.

### Claim 8 (depends on 6)

The method of claim 6 wherein said BMP-6 is human BMP-6 and said BMP-7 is human BMP-7.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody binds to said BMP-6 with a Ka greater than or equal to about 104 M−1.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration of said composition reduces BMP-6 signaling.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mature BMP-6 comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method increases serum iron.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered in an amount sufficient to inhibit an interaction between hemojuvelin and BMP-6.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is a human and the antibody preferably inhibits human BMP-6 over BMP-2, 4, 5, 7 or 9.

### Claim 15

A method of inhibiting hepcidin expression in the liver of a subject, the method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds bone morphogenetic protein-6 (BMP-6) or fragments thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein administration of said composition inhibits liver hepcidin mRNA production.

### Claim 17 (depends on 15)

The method of claim 15, wherein administration of said composition inhibits hepatic hepcidin expression.

### Claim 18 (depends on 15)

The method of claim 15, wherein the subject is a human and administration of said composition inhibits hepcidin expression in human hepatic cells.

### Claim 19 (depends on 15)

The method of claim 15, wherein administration of said composition increases serum transferrin saturation in the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the inhibition is in the presence of BMP-6 and BMP-2, BMP-4, BMP-5, BMP-7, or BMP-9.

### Claim 21 (depends on 15)

The method of claim 15, wherein the antibody binds BMP-7.

### Claim 22 (depends on 21)

The method of claim 21, wherein the antibody specifically binds BMP-6 with higher affinity than BMP-7.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antibody binds BMP-6 with at least 5-fold greater affinity than BMP-7.

### Claim 24 (depends on 21, 22)

The method of any one of claims 21, 22, or 23 wherein said BMP-6 is human BMP-6 and said BMP-7 is human BMP-7.

### Claim 25 (depends on 15)

The method of claim 15, wherein the antibody binds to said BMP-6 with a Ka greater than or equal to about 104 M−1.

### Claim 26 (depends on 15)

The method of claim 15, wherein administration of said composition reduces BMP-6 signaling.

### Claim 27 (depends on 15)

The method of claim 15, wherein the mature BMP-6 comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 28 (depends on 15)

The method of claim 15, wherein the method increases serum iron.

### Claim 29 (depends on 15)

The method of claim 15, wherein the composition is administered in an amount sufficient to inhibit an interaction between hemojuvelin and BMP-6.

### Claim 30 (depends on 15)

The method of claim 15, wherein the subject is a human and the antibody preferably inhibits human BMP-6 over BMP-2, 4, 5, 7 or 9.
